Search

Displaying results 5161 - 5170 of 8698 in total
  1. Drug

    Imidurea

    go.drugbank.com/drugs/DB14075
    Approved

    Imidurea is an antimicrobial preservative used in cosmetics. It acts as a formaldehyde releaser.

  2. Drug

    Quinupramine

    go.drugbank.com/drugs/DB13246
    Approved

    Quinupramine has been approved in France under the brand name Kinupril, as an antidepressant [A175003].

  3. Drug

    ACY001

    go.drugbank.com/drugs/DB06355
    Experimental

  4. Target

    ATP-binding cassette sub-family C member 9

    go.drugbank.com/bio_entities/BE0000469
    TargetHumans

    Subunit of ATP-sensitive potassium channels (KATP). Can form cardiac and smooth muscle-type KATP channels with KCNJ11. KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation (PubMed:9831708). Can form a sulfo...

    Synonyms: Sulfonylurea receptor 2
  5. Drug

    Imexon

    go.drugbank.com/drugs/DB05003
    Investigational

    Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives.

  6. Drug

    Tezampanel

    go.drugbank.com/drugs/DB06354
    Investigational

    Tezampanel is an AMPA receptor antagonist.

  7. Drug

    Brilliant green cation

    go.drugbank.com/drugs/DB11279
    ApprovedVet approved

    Due to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.

  8. Drug

    Tetrodotoxin

    go.drugbank.com/drugs/DB05232
    Investigational

    Tetrodotoxin is being investigated by Wex Pharmaceuticals for the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence. … An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten.

  9. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development. … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]